Market Cap
$710.4M
COLL
COLLEGIUM PHARMACEUTICAL, INC
$22.07 ▲ +1.05%
Prev close $21.84Market cap$710.4M
ConsensusStrong Buy
12-mo target$49.00 (+122.0%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10)32 New Institutional Positions15 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on COLL right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (83%)
Inst. Holders
50 funds
Inst. Value
$1.2B
Inst. Activity
32 buys / 15 sells
Insider Activity
$0.00 buy / $3.4M sell
Insider Net $
-$3.4M
Social Sentiment
33° Cool
SEC Reports
9
Press Releases
3
Price chart 30d -9.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 8, 2026 other
Aug 20, 2026 SEC Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL),
Collegium Pharmaceutical won partial dismissal of Walgreens' breach-of-contract lawsuit in Massachusetts federal court.
COURT-RULING — Impact 5/10
Aug 19, 2026 Event
Aug 13, 2026 SEC Walgreen Co. v. Collegium Pharmaceutical, Inc.
Court ruling (mad) — Docket: 1:26-cv-11242
Collegium Pharmaceutical announced an accelerated share repurchase (ASR) agreement with Jefferies LLC to repurchase $50
8-K — Impact 5/10
Collegium reported Q2 2026 adjusted EPS of $1.92, beating the Street consensus of $1.48 by 29.7%, and revenue of $199.9M
8-K — Impact 6/10
Jun 30, 2026 Inst.
PRINCIPAL FINANCIAL GROUP INC — ADD
1,632,360 shares ($59.1M)
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — DOUBLED
736,925 shares ($26.7M)
Jun 18, 2026 Event
XTAMPZA ER
Supplemental Approval — REMS — OXYCODONE — CAPSULE, EXTENDED RELEASE — ORAL
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
83% rate it Buy or better · 12 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | INITIATE | Outperform | 52% |
| Sep 9, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Sep 9, 2026 | Leerink Partners | INITIATE | Outperform | 49% |
| Aug 19, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Aug 7, 2026 | Piper Sandler | REITERATE | Neutral | 54% |
| Aug 6, 2026 | Needham | MAINTAIN | Buy | 50% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 7 | 2 | 0 | 0 | 83% | |
| Aug 1, 2026 | 3 | 7 | 2 | 0 | 0 | 83% | |
| Jul 1, 2026 | 3 | 7 | 2 | 0 | 0 | 83% | |
| Jun 1, 2026 | 3 | 7 | 2 | 0 | 0 | 83% | |
| May 1, 2026 | 3 | 7 | 2 | 0 | 0 | 83% | |
| Apr 1, 2026 | 3 | 7 | 2 | 0 | 0 | 83% | |
| Mar 1, 2026 | 3 | 7 | 2 | 0 | 0 | 83% | |
| Feb 1, 2026 | 3 | 7 | 2 | 0 | 0 | 83% |
Price targets
Where 8 covering analysts think COLL trades over the next 12 months.
$49.00 +122.0% upside Strong Buy
Current$22.07 Low$43.00 Median$48.50 High$60.00 8 analysts
$43.00$60.00
Analyst rating Strong Buy· 1.5/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
33°
Cool
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 2 bullish, 0 bearish, 2 mixed, 5 neutral · avg impact 4.1/10.Plus 3 press releases.
MIXEDCOURT-RULING5/10
Collegium Pharmaceutical won partial dismissal of Walgreens' breach-of-contract lawsuit in Massachus
Aug 20, 2026
BULLISH8-K5/10
Collegium Pharmaceutical announced an accelerated share repurchase (ASR) agreement with Jefferies LL
Aug 13, 2026
MIXED8-K6/10
Collegium reported Q2 2026 adjusted EPS of $1.92, beating the Street consensus of $1.48 by 29.7%, an
Aug 6, 2026
NEUTRALCLUSTER3/10
Two directors at Collegium Pharmaceutical sold a combined $485K in open-market stock within 11 days
May 18, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 8, 2026
other
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on imp
Aug 19, 2026
Enforcement
Walgreen Co. v. Collegium Pharmaceutical, Inc.
Court ruling (mad) — Docket: 1:26-cv-11242
Aug 14, 2026
short_interest_report
Short Interest: COLL up 28% to 6.5M shares
Settlement 2026-08-14 | Days to cover: 6.66 | ≈20.04% of shares outstanding (est.)
Aug 6, 2026
earnings
Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
– Completed Acquisition of AZSTARYS ® , Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook –
Aug 6, 2026
earnings_calendar
COLL Q2 2026 Earnings Scheduled — 2026-08-06
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $1.81 | $1.49–$2.01 | -19.4% | -2.5% | 0↑ 4↓ | $0.2B | 7 |
| Next Q | $1.92 | $1.49–$2.09 | -5.8% | -3.6% | 0↑ 4↓ | $0.2B | 7 |
| Current FY | $7.36 | $6.65–$7.72 | -0.8% | -1.4% | 0↑ 4↓ | $0.8B | 7 |
| Next FY | $6.68 | $4.52–$8.11 | -9.3% | -1.2% | 1↑ 3↓ | $0.9B | 7 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $1.813 | — |
| 7d ago | $1.822 | -0.009 |
| 30d ago | $1.861 | -0.047 |
| 60d ago | $2.091 | -0.278 |
| 90d ago | $2.077 | -0.263 |
Institutional ownership
Which big funds own COLL (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.2B total value (31,928,332 shares) as of 2026-Q2. Top holders: BlackRock,, Jupiter, Invesco. Net buying activity: 32 institutions added/increased vs 15 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 5,441,202 | $197.0M | 17.0% | — |
| Jupiter Topco LLC | 2,147,072 | $77.7M | 6.7% | — |
| Invesco Ltd. | 1,882,499 | $68.1M | 5.9% | ADD +35.5% |
| FULLER & THALER ASSET MANAGEMENT, INC. | 1,632,781 | $59.1M | 5.1% | — |
| PRINCIPAL FINANCIAL GROUP INC | 1,632,360 | $59.1M | 5.1% | ADD +26.0% |
| STATE STREET CORP | 1,528,881 | $55.3M | 4.8% | — |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 1,405,567 | $50.9M | 4.4% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,381,261 | $50.0M | 4.3% | — |
| RENAISSANCE TECHNOLOGIES LLC | 1,366,549 | $49.5M | 4.3% | — |
| Rubric Capital Management LP | 1,279,611 | $46.3M | 4.0% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| PRINCIPAL FINANCIAL GROUP INC | ADD | 1,295,028 | 1,632,360 | +26.0% | $59.1M |
| MILLENNIUM MANAGEMENT LLC | DOUBLED | 360,826 | 736,925 | +104.2% | $26.7M |
| Qube Research & Technologies Ltd | TRIM | 621,935 | 431,447 | -30.6% | $15.6M |
| D. E. Shaw & Co., Inc. | TRIM | 530,698 | 338,383 | -36.2% | $12.2M |
| MARSHALL WACE, LLP | TRIM | 748,812 | 253,353 | -66.2% | $9.2M |
| UBS Group AG | DOUBLED | 43,337 | 206,070 | +375.5% | $7.5M |
| Nuveen, LLC | ADD | 71,990 | 107,947 | +49.9% | $3.9M |
| BARCLAYS PLC | ADD | 71,949 | 107,670 | +49.6% | $3.9M |
| Quantinno Capital Management LP | ADD | 56,242 | 98,592 | +75.3% | $3.6M |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | 25,841 | 89,443 | +246.1% | $3.2M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 37 transactions. Net -$3.4M — $0.00 bought, $3.4M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | SANTINI GINO | Director | EXERCISE | 8,700 | $16.49 | $143.5K |
| May 18, 2026 | Freund John Gordon | Director | SELL | 20 | $34.05 | $681.00 |
| May 15, 2026 | Freund John Gordon | Director | EXERCISE | 8,700 | $16.49 | $143.5K |
| May 15, 2026 | Freund John Gordon | Director | SELL | 4,127 | $34.54 | $142.5K |
| May 14, 2026 | Freund John Gordon | Director | AWARD | 8,741 | — | — |
| May 14, 2026 | Glancy Donovan Michael | Director | AWARD | 17,482 | — | — |
| May 14, 2026 | SANTINI GINO | Director | AWARD | 8,741 | — | — |
| May 14, 2026 | Lurker Nancy | Director | AWARD | 8,741 | — | — |
| May 14, 2026 | Balice-Gordon Rita J. | Director | AWARD | 8,741 | — | — |
| May 14, 2026 | Paya Carlos V | Director | AWARD | 8,741 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for COLL.
Shares short
5,675,115
Settlement Sep 15, 2026
Change vs prior
-6.4%
Semi-monthly cycle
Days to cover
6.0
At avg daily volume
Of shares outstanding
≈17.4%
Estimate — not % of float
All COLL filing & press-release reports (12)
- COURT-RULING reportAug 20, 2026
- 8-K reportAug 13, 2026
- 8-K reportAug 6, 2026
- CLUSTER reportMay 18, 2026
- PRESS-RELEASE reportMay 12, 2026
- 144 reportMay 11, 2026
- PRESS-RELEASE reportApr 23, 2026
- 8-K reportApr 7, 2026
- PRESS-RELEASE reportMar 19, 2026
- CLUSTER reportMar 11, 2026
- PRESS-RELEASE reportMar 3, 2026
- 8-K reportFeb 26, 2026